Parathyroid glands in uraemic patients with refractory hyperparathyroidism: Histopathology and p53 protein expression analysis

Histopathology

Volumn 33, Issue 1, 1998, Pages 46-51

  Martin, L N C ^a   Kayath, M J ^a   Vieira, J G H ^a   Nose Alberti V ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hyperparathyroidism; p53; Parathyroid gland; Parathyroid hyperplasia; Uraemia

Indexed keywords

PROTEIN P53;

ACINAR CELL; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NODULAR HYPERPLASIA; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; THYROID PARAFOLLICULAR CELL; UREMIA;

ADOLESCENT; ADULT; AGED; CELL NUCLEUS; FEMALE; HUMANS; HYPERPARATHYROIDISM; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; TUMOR SUPPRESSOR PROTEIN P53; UREMIA;

EID: 0031877666     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. DeLells RA. Atlas of Tumor Pathology - Tumors of the Parathyroid Gland, third series, Washington DC: Armed Forces Institute of Pathology, 1991.
2. Tominaga Y, Sato K, Tanaka Y et al. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin. Nephrol. 1995: 44 (Suppl. 1); S42-S47.
3. Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J. Clin. Endocrinol. Metab. 1985: 61; 601-606.
4. Slatopolsky E, Hilker SL, Delmez J et al. The parathyroid-calcitriol axis in healthy and chronic renal failure. Kidney Int. 1990: 38 (Suppl. 29); S41.
5. Krause MW, Hedinger CE. Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Human Pathol, 1985: 16; 772-784.
6. Galbraith SC, Quartes LD. Tertiary hyperparathyroidism and refractory secondary hyperparathyroidism. In Murray JF ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd edn. Chicago: Lippincott-Raven, 1997; 192-197.
7. Chcn PL, Chen YM, Bookstein R et al. Genetic mechanisms of tumour suppression by the human p53 gene. Science 1990: 250; 1576-1580.
8. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem. 1996: 42; 858-868.
9. Subramaniam P, Wilkinson S, Shepherd J J. p53 tumour suppressor gene expression in hyperparathyroidism. Aust. NZ J. Surg. 1996: 66; 303-304.
10. Cryns VL, Rubio MP, Thor AD et al. P53 abnormalities in human parathyroid carcinoma. J. Clin. Endocrinol. Metab. 1994: 78; 1320-1324.
11. Vargas MP, Vargas HI, Kleiner DE et al. The role of prognostic markers (MIB-1, RB, and bel-2) in the diagnosis of parathyroid tumors. Mod. Pathol. 1997: 10; 12-17.
12. Wang W, Johansson H, Kvasnicka T et al. Detection of apoptotic cells and expression of ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. APMIS 1996: 104; 789-796.
13. Vieira JGH, Nishida SK, Kasamatsu TS et al. Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Brazil. J. Med. Biol. Res. 1994: 27; 2379-2382.
14. Falcheti A, Bale AE, Amorosi A et al. Progression of uremic hyperparathyroidism involves allelic loss of chromosome 11. J. Clin. Endocrinol. Metab. 1993: 76; 139-144.
15. Akerström G, Malmaeus J, Grimelius L et al. Histological changes in parathyroid glands in subclinical and clinical renal disease. Scand. J. Urol. Nephrol. 1984: 18; 75-84.
16. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. J. Histochem. Cytochem. 1981: 29; 577-580.
17. Grimelius L, Bondenson L. Histological diagnosis of parathyroid diseases. Pathol. Res. Pract. 1995: 191; 353-365.
18. Hsu DW, Hakim F, Biller BMK et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J. Neurosurg. 1993: 78; 753-761.
19. Wallfelt CH, Larsson R, Gylfe E et al. Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: Implication for parathyroid autotransplantation. World J. Surg. 1988: 12; 431.
20. Hakim JP, Levine MA. Absence of p53 point mutations in parathyroid adenoma and carcinoma. J. Clin. Endocrinol. Metab. 1994: 78; 103-106.
21. Wang LD, Hong JY. Qui SL et al. Accumulation of p53 protein in esophageal precancerous lesions: a possible early hiomarker for carcinogenesis. Cancer Res. 1993: 53; 1783-1787.
22. Ahomadegbe JC, Barrois M, Fogel S et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncagene 1995: 10; 1217-1227.
23. Meyers FJ, Chi S, Fishman JR et al. p53 mutations in benign prostatic hyperplasia. J. Nat. Cancer Inst. 1993: 85; 1856-1858.